Compare Global Payments Inc (GPN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs 10X Genomics Inc — how do they compare? Global Payments Inc trades at $84.87 (market cap $22.72B), while 10X Genomics Inc trades at $58.08 (market cap $7.61B). The key difference: Global Payments Inc is far larger — about 3× 10X Genomics Inc's market cap, and Global Payments Inc pays a 1.16% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| GPN | TXG | |
|---|---|---|
Market Cap | $22.72B | $7.61B |
Sector | Industrials | Health |
52-Week High | $90.01 | $58.57 |
52-Week Low | $62.47 | $11.34 |
Enterprise Value | $40.87B | $7.14B |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $86.13, up slightly by 0.01% today, with a bullish technical signal from moving averages and strong quarterly EPS beats. The company reported Q2 2026 EPS of $3.46, exceeding expectations, but faces headwinds with a negative net income margin of -9.15% in 2026. Recent news highlights Genius platform momentum driving earnings growth, though full-year revenue guidance was trimmed due to Middle East challenges.
Outlook remains cautiously optimistic with a consensus price target of $96.67, offering 12% upside, supported by analyst buy ratings at 58.7%. Key risks include margin pressure from rising costs and intense fintech competition, while institutional interest persists with recent investments like Delta Global Management's $1.74 million stake in Q1 2026.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
